148 related articles for article (PubMed ID: 24096622)
1. From Papanicolaou to papillomaviruses: evolving challenges in cervical cancer screening in the era of human papillomavirus vaccination.
Safaeian M; Sherman ME
J Natl Cancer Inst; 2013 Oct; 105(20):1524-6. PubMed ID: 24096622
[No Abstract] [Full Text] [Related]
2. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study.
Ikenberg H; Bergeron C; Schmidt D; Griesser H; Alameda F; Angeloni C; Bogers J; Dachez R; Denton K; Hariri J; Keller T; von Knebel Doeberitz M; Neumann HH; Puig-Tintore LM; Sideri M; Rehm S; Ridder R;
J Natl Cancer Inst; 2013 Oct; 105(20):1550-7. PubMed ID: 24096620
[TBL] [Abstract][Full Text] [Related]
3. Surrogate biomarkers of HPV infection in cervical neoplasia screening and diagnosis.
Keating JT; Ince T; Crum CP
Adv Anat Pathol; 2001 Mar; 8(2):83-92. PubMed ID: 11236957
[TBL] [Abstract][Full Text] [Related]
4. The significance of HPV L1 and Ki-67 detection in cervical intraepithelial neoplasm screening.
Luo Y; Cai M; Shen P; Chen H; Yao J
Minerva Med; 2019 Dec; 110(6):586-587. PubMed ID: 31295980
[No Abstract] [Full Text] [Related]
5. [Clinical value of p16/Ki-67 immunocytochemical dual staining in cervical cancer screening].
Wang HR; Liao GD; Chen W; Qiao YL; Jiang Y
Zhonghua Zhong Liu Za Zhi; 2017 Aug; 39(8):636-640. PubMed ID: 28835090
[No Abstract] [Full Text] [Related]
6. Clinical value of fully automated p16/Ki-67 dual staining in the triage of HPV-positive women in the Norwegian Cervical Cancer Screening Program.
Ovestad IT; Dalen I; Hansen E; Loge JL; Dybdahl BM; Dirdal MB; Moltu P; Berland JM
Cancer Cytopathol; 2017 Apr; 125(4):283-291. PubMed ID: 27918650
[TBL] [Abstract][Full Text] [Related]
7. Using biomarkers as objective standards in the diagnosis of cervical biopsies.
Galgano MT; Castle PE; Atkins KA; Brix WK; Nassau SR; Stoler MH
Am J Surg Pathol; 2010 Aug; 34(8):1077-87. PubMed ID: 20661011
[TBL] [Abstract][Full Text] [Related]
8. Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women.
Clarke MA; Cheung LC; Castle PE; Schiffman M; Tokugawa D; Poitras N; Lorey T; Kinney W; Wentzensen N
JAMA Oncol; 2019 Feb; 5(2):181-186. PubMed ID: 30325982
[TBL] [Abstract][Full Text] [Related]
9. [Results of pap smears and immunocytochemical detection of the p16 and Ki67 proteins in women with cervical intraepithelial neoplasia and cervical cancer].
Rokita W; Skawiński D; Zmelonek-Znamirowska A; Kedzia W; Karowicz-Bilińska A; Spaczyński R; Spaczyński M
Ginekol Pol; 2012 Nov; 83(11):822-6. PubMed ID: 23379189
[TBL] [Abstract][Full Text] [Related]
10. Beyond P16/Ki67 dual-stain cytology: Exploring alternative biomarkers for diagnosing cervical cancer and its precursors.
Rauf SA; Zehra SA; Shah HH
BJOG; 2024 Jan; 131(1):115-116. PubMed ID: 37345409
[No Abstract] [Full Text] [Related]
11. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data.
Uijterwaal MH; Polman NJ; Witte BI; van Kemenade FJ; Rijkaart D; Berkhof J; Balfoort-van der Meij GA; Ridder R; Snijders PJ; Meijer CJ
Int J Cancer; 2015 May; 136(10):2361-8. PubMed ID: 25345358
[TBL] [Abstract][Full Text] [Related]
12. MN and Ki67 (MIB-1) in uterine cervix carcinoma: novel biomarkers with divergent utility.
Costa MJ
Hum Pathol; 1996 Mar; 27(3):217-9. PubMed ID: 8600033
[No Abstract] [Full Text] [Related]
13. Clinical efficacy of p16/Ki-67 dual-stained cervical cytology in secondary prevention of cervical cancer.
Celewicz A; Celewicz M; Wężowska M; Chudecka-Głaz A; Menkiszak J; Urasińska E
Pol J Pathol; 2018; 69(1):42-47. PubMed ID: 29895125
[TBL] [Abstract][Full Text] [Related]
14. Triaging borderline/mild dyskaryotic Pap cytology with p16/Ki-67 dual-stained cytology testing: cross-sectional and longitudinal outcome study.
Uijterwaal MH; Witte BI; Van Kemenade FJ; Rijkaart D; Ridder R; Berkhof J; Balfoort-van der Meij GA; Bleeker MC; Snijders PJ; Meijer CJ
Br J Cancer; 2014 Mar; 110(6):1579-86. PubMed ID: 24518601
[TBL] [Abstract][Full Text] [Related]
15. Reducing overtreatment associated with overdiagnosis in cervical cancer screening-A model-based benefit-harm analysis for Austria.
Sroczynski G; Esteban E; Widschwendter A; Oberaigner W; Borena W; von Laer D; Hackl M; Endel G; Siebert U
Int J Cancer; 2020 Aug; 147(4):1131-1142. PubMed ID: 31872420
[TBL] [Abstract][Full Text] [Related]
16. Improved abnormal Pap smear triage using cervical cancer biomarkers.
Killeen JL; Dye T; Grace C; Hiraoka M
J Low Genit Tract Dis; 2014 Jan; 18(1):1-7. PubMed ID: 23760145
[TBL] [Abstract][Full Text] [Related]
17. Interobserver reproducibility and accuracy of p16/Ki-67 dual-stain cytology in cervical cancer screening.
Wentzensen N; Fetterman B; Tokugawa D; Schiffman M; Castle PE; Wood SN; Stiemerling E; Poitras N; Lorey T; Kinney W
Cancer Cytopathol; 2014 Dec; 122(12):914-20. PubMed ID: 25132656
[TBL] [Abstract][Full Text] [Related]
18. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial.
Wright TC; Behrens CM; Ranger-Moore J; Rehm S; Sharma A; Stoler MH; Ridder R
Gynecol Oncol; 2017 Jan; 144(1):51-56. PubMed ID: 28094038
[TBL] [Abstract][Full Text] [Related]
19. Is it practical to add the p16/Ki67 immunohistochemical dual staining into liquid-based cytology for cervical cancer screening?
Li YT; Lee NR; Chang WH
Taiwan J Obstet Gynecol; 2024 May; 63(3):437-438. PubMed ID: 38802218
[No Abstract] [Full Text] [Related]
20. Comparison of the sensitivity and specificity of p16/Ki-67 dual staining and HPV DNA testing of abnormal cervical cytology in the detection of histology proven cervical intraepithelial neoplasia grade 2 and above (CIN 2+).
Tay TKY; Lim KL; Hilmy MH; Thike AA; Goh ST; Song LH; Hwang JSG; Mantoo S
Malays J Pathol; 2017 Dec; 39(3):257-265. PubMed ID: 29279588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
